The induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib

Cancer Immunology, Immunotherapy

Volumn 65, Issue 3, 2016, Pages 273-282

  Heine, Annkristin ^a,b   Schilling, Judith ^b   Grünwald, Barbara ^c   Krüger, Achim ^c   Gevensleben, Heidrun ^a   Held, Stefanie Andrea Erika ^a   Garbi, Natalio ^b   Kurts, Christian ^b   Brossart, Peter ^a   Knolle, Percy ^b,c   Diehl, Linda ^d   Höchst, Bastian ^b,c  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF HAMBURG   (Germany)

Author keywords

Immunomodulation; Immunotherapy; Myeloid derived suppressor cells; Tyrosine kinase inhibitors

Indexed keywords

CD14 ANTIGEN; CD8 ANTIGEN; DASATINIB; FLUOROURACIL; GEMCITABINE; HLA DR ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; CARBANILAMIDE DERIVATIVE; CELECOXIB; INDOLE DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MONOCYTE; MYELOID DERIVED SUPPRESSOR CELL; PRIORITY JOURNAL; STELLATE CELL; SUPPRESSOR CELL; ANALOGS AND DERIVATIVES; BONE MARROW CELL; CELL CULTURE; CELL DIFFERENTIATION; DOSE RESPONSE; DRUG EFFECTS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; PHYSIOLOGY;

CELECOXIB; CELL DIFFERENTIATION; CELLS, CULTURED; DASATINIB; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPATIC STELLATE CELLS; HUMANS; IMMUNE TOLERANCE; INDOLES; MONOCYTES; MYELOID CELLS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES;

EID: 84959531918     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1790-5     Document Type: Article

References (41)

1. De Veirman K, Van Valckenborgh E, Lahmar Q, Geeraerts X, De Bruyne E, Menu E, Van Riet I, Vanderkerken K, Van Ginderachter JA (2014) Myeloid-derived suppressor cells as therapeutic target in hematological malignancies. Front Oncol 4:349. doi:10.3389/fonc.2014.00349
2. Diaz-Montero CM, Finke J, Montero AJ (2014) Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications. Semin Oncol 41:174–184. doi:10.1053/j.seminoncol.2014.02.003
3. Escors D, Liechtenstein T, Perez-Janices N et al (2013) Assessing T-cell responses in anticancer immunotherapy: dendritic cells or myeloid-derived suppressor cells? Oncoimmunology 2:e26148. doi:10.4161/onci.26148
4. Filipazzi P, Huber V, Rivoltini L (2012) Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother 61:255–263. doi:10.1007/s00262-011-1161-9
5. Greten TF, Manns MP, Korangy F (2011) Myeloid derived suppressor cells in human diseases. Int Immunopharmacol 11:802–807. doi:10.1016/j.intimp.2011.01.003
6. Medina-Echeverz J, Aranda F, Berraondo P (2014) Myeloid-derived cells are key targets of tumor immunotherapy. Oncoimmunology 3:e28398. doi:10.4161/onci.28398
7. Nagaraj S, Gabrilovich DI (2008) Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res 68:2561–2563. doi:10.1158/0008-5472.CAN-07-6229
8. Nagaraj S, Gabrilovich DI (2010) Myeloid-derived suppressor cells in human cancer. Cancer J 16:348–353. doi:10.1097/PPO.0b013e3181eb3358
9. Solito S, Marigo I, Pinton L, Damuzzo V, Mandruzzato S, Bronte V (2014) Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci 1319:47–65. doi:10.1111/nyas.12469
10. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9:162–174. doi:10.1038/nri2506
11. Nagaraj S, Gabrilovich DI (2007) Myeloid-derived suppressor cells. Adv Exp Med Biol 601:213–223
12. Talmadge JE (2007) Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res 13:5243–5248. doi:10.1158/1078-0432.CCR-07-0182
13. + myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. J Transl Med 9:90. doi:10.1186/1479-5876-9-90
14. Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, Mandruzzato S, Bronte V (2010) Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 22:238–244. doi:10.1016/j.coi.2010.01.021
15. Wesolowski R, Markowitz J, Carson WE 3rd (2013) Myeloid derived suppressor cells-a new therapeutic target in the treatment of cancer. J Immunother Cancer 1:10. doi:10.1186/2051-1426-1-10
16. Hochst B, Schildberg FA, Sauerborn P et al (2013) Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion. J Hepatol 59:528–535. doi:10.1016/j.jhep.2013.04.033
17. Held SA, Heine A, Mayer KT, Kapelle M, Wolf DG, Brossart P (2013) Advances in immunotherapy of chronic myeloid leukemia CML. Curr Cancer Drug Targets 13:768–774
18. Jabbour E, Cortes J, Kantarjian H (2011) Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors. Cancer 117:897–906. doi:10.1002/cncr.25656
19. + peripheral blood progenitor cells. Blood 103:538–544. doi:10.1182/blood-2003-03-0975
20. Ozao-Choy J, Ma G, Kao J et al (2009) The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 69:2514–2522. doi:10.1158/0008-5472.CAN-08-4709
21. Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V, Zhang R, Szpurka H, Maciejewski JP (2008) Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 111:1366–1377. doi:10.1182/blood-2007-04-084814
22. Heine A, Held SA, Daecke SN, Wallner S, Yajnanarayana SP, Kurts C, Wolf D, Brossart P (2013) The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood 122:1192–1202. doi:10.1182/blood-2013-03-484642
23. Heine A, Held SA, Daecke SN, Riethausen K, Kotthoff P, Flores C, Kurts C, Brossart P (2015) The VEGF-receptor inhibitor axitinib impairs dendritic cell phenotype and function. PLoS One 10:e0128897. doi:10.1371/journal.pone.0128897
24. Kao J, Ko EC, Eisenstein S, Sikora AG, Fu S, Chen SH (2011) Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit Rev Oncol Hematol 77:12–19. doi:10.1016/j.critrevonc.2010.02.004
25. Lowe DB, Bose A, Taylor JL, Tawbi H, Lin Y, Kirkwood JM, Storkus WJ (2014) Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma. Oncoimmunology 3:e27589. doi:10.4161/onci.27589
26. Motoshima T, Komohara Y, Horlad H et al (2015) Sorafenib enhances the antitumor effects of anti-CTLA-4 antibody in a murine cancer model by inhibiting myeloid-derived suppressor cells. Oncol Rep 33:2947–2953. doi:10.3892/or.2015.3893
27. Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R, Ochoa AC (2009) Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 69:1553–1560. doi:10.1158/0008-5472.CAN-08-1921
28. Ardeshna KM, Pizzey AR, Devereux S, Khwaja A (2000) The PI3 kinase, p38 SAP kinase, and NF-kappaB signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells. Blood 96:1039–1046
29. Hipp MM, Hilf N, Walter S, Werth D, Brauer KM, Radsak MP, Weinschenk T, Singh-Jasuja H, Brossart P (2008) Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 111:5610–5620. doi:10.1182/blood-2007-02-075945
30. + T cell memory responses. J Immunol 172:6047–6056
31. Iclozan C, Antonia S, Chiappori A, Chen DT, Gabrilovich D (2013) Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother 62:909–918. doi:10.1007/s00262-013-1396-8
32. Obermajer N, Wong JL, Edwards RP, Odunsi K, Moysich K, Kalinski P (2012) PGE(2)-driven induction and maintenance of cancer-associated myeloid-derived suppressor cells. Immunol Invest 41:635–657. doi:10.3109/08820139.2012.695417
33. Li RJ, Liu L, Gao W, Song XZ, Bai XJ, Li ZF (2014) Cyclooxygenase-2 blockade inhibits accumulation and function of myeloid-derived suppressor cells and restores T cell response after traumatic stress. J Huazhong Univ Sci Technol Med Sci 34:234–240. doi:10.1007/s11596-014-1264-6
34. Nefedova Y, Fishman M, Sherman S, Wang X, Beg AA, Gabrilovich DI (2007) Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. Cancer Res 67:11021–11028. doi:10.1158/0008-5472.CAN-07-2593
35. Heine A, Held SA, Bringmann A, Holderried TA, Brossart P (2011) Immunomodulatory effects of anti-angiogenic drugs. Leukemia 25:899–905. doi:10.1038/leu.2011.24
36. Bailey A, McDermott DF (2013) Immune checkpoint inhibitors as novel targets for renal cell carcinoma therapeutics. Cancer J 19:348–352. doi:10.1097/PPO.0b013e31829e3153
37. McDermott DF, Drake CG, Sznol M et al (2015) Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol 33:2013–2020. doi:10.1200/JCO.2014.58.1041
38. Motzer RJ, Rini BI, McDermott DF et al (2015) Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II Trial. J Clin Oncol 33:1430–1437. doi:10.1200/JCO.2014.59.0703
39. Ko JS, Rayman P, Ireland J, Swaidani S, Li G, Bunting KD, Rini B, Finke JH, Cohen PA (2010) Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res 70:3526–3536. doi:10.1158/0008-5472.CAN-09-3278
40. Ko JS, Zea AH, Rini BI et al (2009) Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 15:2148–2157. doi:10.1158/1078-0432.CCR-08-1332
41. + dendritic cell frequency predicts progression-free survival. Clin Cancer Res 14:5884–5892. doi:10.1158/1078-0432.CCR-08-0656